aap Implantate has outlined its growth strategy for 2015, which includes plans to grow specifically in the trauma sector.
Here are four key points from their growth strategy:
• For the company as a whole, the management board expects sales to total between $37.6 million and $39.9 million.
• The company forecasts EBITDA in the financial year 2015 of between $2.8 million and $3.9 million.
• For the full year 2015 the company anticipates trauma sales growth to be between $16.9 million and $17.5 million. Its LOQTEQ product family is expected to be the main driver of this development.
• Sales in the biomaterials business are expected to grow by 10 percent.
The company is also still in talks with selected strategic investors and private equity companies on a transaction for aap Biomaterials that is anticipated in the first quarter of 2015.
More articles on devices:
27 spine devices receive FDA 510(k) clearance in January
MiMedx withdraws complaint against Organogenesis
NuVasive COO sells 15k shares — 5 things to know